Achieve Life Sciences, Inc.
NASDAQ:ACHVBiotechnology
Healthcare
$6.78 -7.00%
-$0.38 today
- Market cap
- $697.68M
- Beta
- 2.26
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.97
52W Low $2.00High $6.16
Volume 1.09M
Average 1.44M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$49.47M
FY 2025 · Annual
Investing Cash Flow
$6.11M
FY 2025 · Annual
Financing Cash Flow
$51.53M
FY 2025 · Annual
+6.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.15M) | (42.35M) | (29.82M) | (39.83M) | (54.65M) |
| Depreciation & Amortization | 250K | 236K | 228K | 229K | 228K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.19M | 3.27M | 3.44M | 5.33M | 8.76M |
| Change in Working Capital | 1.23M | 79K | (778K) | 2.41M | (4.27M) |
| Accounts Receivables | (153K) | 48K | 0 | 111K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 509K | 799K | (1.04M) | 1.33M | (1.08M) |
| Other Working Capital | 878K | (768K) | 264K | 969K | (3.18M) |
| Other Non-Cash Items | 41K | 1.2M | 2.45M | 2.09M | 460K |
| Operating Cash Flow | (29.44M) | (37.57M) | (24.48M) | (29.77M) | (49.47M) |
| Capital Expenditures | 0 | 0 | (21K) | 0 | (3K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (47.89M) | (24.76M) |
| Sales of Investments | 0 | 0 | 0 | 26.31M | 30.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 3K |
| Investing Cash Flow | 0 | 0 | (21K) | (21.58M) | 6.11M |
| Debt Repayment | 14.93M | 0 | 0 | (8.3M) | 5M |
| Common Stock Issued | 21.34M | 19.21M | 15.3M | 56.08M | 46.53M |
| Common Stock Repurchased | 0 | 0 | (30K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 338K | 103K | 7K | 746K | 0 |
| Financing Cash Flow | 36.61M | 19.32M | 15.28M | 48.53M | 51.53M |
| Effect of Forex Changes | (1K) | 3K | (3K) | 30K | 3K |
| Net Change in Cash | 7.17M | (18.25M) | (9.23M) | (2.79M) | 8.18M |
| Free Cash Flow | (29.44M) | (37.57M) | (24.5M) | (29.77M) | (49.47M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$54.6M
+ D&A$228.0K
+ Stock-Based Comp$8.8M
+ Deferred Tax$0
- Working Capital-$4.3M
+ Other Non-Cash$460.0K
= Operating Cash Flow-$49.5M
- Capex-$3.0K
= Free Cash Flow-$49.5M
Analysis
FY2025 free cash flow is -$49.5M. FCF conversion is 90.5% of net income. Operating cash flow was -$49.5M, with capex of -$3.0K. The largest bridge item is Stock-Based Comp at $8.8M.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| SC 13G | SC 13G filing | Aug 17, 2026 |
Does ACHV generate free cash flow?
Achieve Life Sciences, Inc. (ACHV) generated -$49.47M of free cash flow in fiscal 2025.
How much operating cash flow does ACHV produce?
Operating cash flow was -$49.47M, before capital expenditures of $3,000.00.
Continue the stock analysis
Jump to another research area for this company.